HDM1702
GLP-1 · s.c. · Huadong Medicine
Summary
- Also known as
- Zhongmei Huadong
- Mechanism
- GLP-1
- Route
- s.c.
- Company
- Huadong Medicine
- Highest development stage
- filed
- Status (as of data cut)
- Semaglutide follow-on: phase 3 equivalence to Wegovy; NDAs accepted in China (T2D Mar 2025; weight Apr 2026) verify
- Next milestone
- China approval
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Phase 3 equivalence versus Wegovy met (semaglutide follow-on) | HDM1702 vs Wegovy (EASD 2026) |
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDM1702 vs Wegovy (bioequivalence) | HDM1702 2.4 mg vs semaglutide (Wegovy): −16.27 % | obesity china | 44 | 462 | — | −15.2 % | — | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07036172 · China Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients | Obesity | Phase 3 | recruiting | 2025-01 → 2026-04 | 460 | recruiting | NCT07036172 |
Primary sources
How to cite this page
Cite the primary publication for any single result; every value above links to it.